EPAS1 and atherosclerosis: HIF-1α and HIF-2α play an antagonistic effect in the long-term activation process, which may contribute to the progression of chronic heart failure, atherosclerosis, hypertension, vascular disease, and chronic kidney disease cardiac failure [32].